AstraZeneca (LON:AZN) Earns Overweight Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their overweight rating on shares of AstraZeneca (LON:AZN) in a report published on Monday morning, MarketBeat Ratings reports.

Several other research analysts have also recently commented on the company. Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Thursday, July 25th. Jefferies Financial Group raised their target price on shares of AstraZeneca from GBX 71 ($0.94) to GBX 74 ($0.98) and gave the company a hold rating in a research note on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a hold rating and set a £110 ($145.31) price target on shares of AstraZeneca in a research report on Tuesday, September 3rd. Berenberg Bank reissued a buy rating and issued a £150 ($198.15) price objective on shares of AstraZeneca in a research report on Monday, September 2nd. Finally, Citigroup restated a buy rating on shares of AstraZeneca in a research note on Tuesday, May 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of £105.53 ($139.41).

AstraZeneca Trading Up 0.4 %

AstraZeneca stock opened at £118.98 ($157.17) on Monday. The company has a debt-to-equity ratio of 84.97, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a 50-day moving average of £125.74 and a 200-day moving average of £119.31. The company has a market cap of £184.42 billion, a price-to-earnings ratio of 3,813.46, a P/E/G ratio of 0.93 and a beta of 0.17. AstraZeneca has a one year low of GBX 9,461 ($124.98) and a one year high of £133.88 ($176.86).

AstraZeneca Cuts Dividend

The business also recently disclosed a dividend, which was paid on Monday, September 9th. Stockholders of record on Thursday, August 8th were given a GBX 77.60 ($1.03) dividend. This represents a dividend yield of 0.64%. The ex-dividend date was Thursday, August 8th. AstraZeneca’s payout ratio is presently 7,500.00%.

Insider Transactions at AstraZeneca

In related news, insider Michel Demare purchased 2,000 shares of the stock in a transaction on Friday, September 13th. The shares were purchased at an average cost of GBX 118 ($1.56) per share, with a total value of £2,360 ($3,117.57). 0.04% of the stock is currently owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.